November 13, 2026 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · DOI: 10.1200/JCO-26-01039

Early Treatment Failure in Patients With Relapsed/Refractory Multiple Myeloma Receiving Bispecific T-Cell Engagers: Development and Validation of the CHARGE Prognostic Index.

Listen to this summary

This study developed and externally validated the CHARGE index, a prognostic score for predicting progression-free survival in relapsed/refractory multiple myeloma patients receiving BCMA- or GPRC5D-directed bispecific T-cell engagers. Six readily available factors (high-risk cytogenetics, hyperferritinemia, anemia, early relapse, poor performance status, and prior BCMA-directed therapy) stratified patients into low-, intermediate-, and high-risk groups with median PFS of 21.8, 7.1, and 1.6 months, respectively, and these distinctions held in an independent cohort. The index offers a simple, validated tool to guide prognosis and identify patients at high risk of early treatment failure with bispecific T-cell engagers.

Saurabh Zanwar, Doris K Hansen, Oren Pasvolsky, Carlyn Tan, Lauren C Peres, Utkarsh Goel, Rakesh Popat, Aimaz Afrough, Sireesha Asoori, Masooma Rana, Mrugakshi Dave, Andrew Portuguese, Efstathios Kastritis, James A Davis, Joaquin Martinez-Lopez, Douglas Sborov, Jana Mihalyova, Susan Bal, Murali Janakiram, Darren Pan, Leyla Shune, Christopher Ferreri, Noa Biran, Megan Herr, Ariel Grajales-Cruz, Jack Khouri, Andre De Menezes Silva Corraes, Omar Castaneda Puglianini, Emily C Liang, Eli Zolotov, Tiffany Richards, Mahmoud Gaballa, Gliceida Galarza Fortuna, Kelley Julian, Kimberly Green, Aishwarya Sannareddy, Larry D Anderson, Shahzad Raza, Danai Dima, Lekha Mikkilineni, Faiz Anwer, Shaji Kumar, Saad Usmani, Chiung-Yu Huang, Hira Mian, Surbhi Sidana, Krina Patel, Thomas Martin, Yi Lin, Luciano Costa

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

More from Journal of clinical oncology : official journal of the American Society of Clinical Oncology

View all →

Nov 20, 2026 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Alectinib as Neoadjuvant Treatment in Potentially Resectable Stage III Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: ALNEO Phase II Trial (GOIRC-01-2020-ML42316).

Nov 20, 2026 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Effect of a Multidisciplinary Intervention on Fatigue in Lymphoma Survivors With Persistent Fatigue: A Randomized Controlled Trial (the REFUEL trial).

Nov 20, 2026 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Reach of State-Mandated Insurance Coverage for Fertility Preservation in Patients With Cancer.

Nov 17, 2026 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Breast Carcinoma: 5-Year Results of the Multicenter, Randomized, Phase III IRMA Trial.

Nov 13, 2026 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Dasatinib Dose Optimization With Weekend Drug Holiday for Improved Tolerability in Chronic Myeloid Leukemia (DasaHIT): A German Chronic Myeloid Leukemia Alliance Randomized Trial.

Nov 12, 2026 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Second Cancer Risk in Female Survivors of Hodgkin Lymphoma: A National Cohort Analysis Across Treatment Eras.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play